A Phase I/II and Target Validation Study of TAK-580 (MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs TAK 580 (Primary)
- Indications CNS cancer; Glioma; Neurofibromatoses; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 01 Mar 2018 Status changed from not yet recruiting to recruiting.